. . . . . . . "192329-42-3"@en . . " "@en . "AG3340"@en . . "Prinomastat"@en . . . "# Shalinsky DR, Brekken J, Zou H, McDermott CD, Forsyth P, Edwards D, Margosiak S, Bender S, Truitt G, Wood A, Varki NM, Appelt K: Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials. Ann N Y Acad Sci. 1999 Jun 30;878:236-70. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10415735 # Deryugina EI, Ratnikov BI, Strongin AY: Prinomastat, a hydroxamate inhibitor of matrix metalloproteinases, has a complex effect on migration of breast carcinoma cells. Int J Cancer. 2003 May 1;104(5):533-41. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12594807 # Scatena R: Prinomastat, a hydroxamate-based matrix metalloproteinase inhibitor. A novel pharmacological approach for tissue remodelling-related diseases. Expert Opin Investig Drugs. 2000 Sep;9(9):2159-65. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11060800"@en . "Investigated for use/treatment in brain cancer, lung cancer, and prostate cancer."@en . . "AG3340 is a synthetic hydroxamic acid derivative with potential antineoplastic activity. AG3340 inhibits matrix metalloproteinases (MMPs) (specifically, MMP-2, 9, 13, and 14), thereby inducing extracellular matrix degradation, and inhibiting angiogenesis, tumor growth and invasion, and metastasis. As a lipophilic agent, AG3340 crosses the blood-brain barrier. "@en . . . . . . . "2-5 hours"@en . . . . . . . . . . . . . . "investigational"@en . .